ASCO 2023 | LuPARP: 177Lu-PSMA-617 and PARP inhibitor combination for prostate cancer

Shahneen Sandhu, MBBS, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the LuPARP study (NCT03874884), which combined two agents in clinic. 177Lu-PSMA-617 is a radionucleotide treatment which targets prostate specific membrane antigen which is expressed in prostate cancer. 177Lu-PSMA-617 has shown benefits in terms of progression-free survival (PFS) and overall survival (OS). Despite this, disease progression still occurs when this therapy is used. Preclinical and clinical data show that PARP inhibitors may be used to increase the efficacy of radiation in a combination strategy. It was suggested that a PARP inhibitor could improve the efficacy of 177Lu-PSMA-617, thus allowing for favorable and durable responses. The main objective was to form the recommended Phase II dose for combination therapy, whilst also assessing the safety and efficacy of this combination therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.